Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Open accessThe DOI matches its Crossref record; 647 of the 647 references it cites were found in a registry or an index; 336 of the 490 sources its claims cite were checked for support.
Overview
CoChat Summary
TL;DR
The 2024 Lancet Commission update adds uncorrected vision impairment and high LDL cholesterol to the 12 previously identified modifiable dementia risk factors, estimating that 14 factors account for 45.3% of dementia PAF. It concludes that risk can be reduced across the lifecourse, while anti-amyloid antibodies show small 18-month effects with uncertain clinical importance and implementation challenges.
Key findings
- The 14 risk factors account for a weighted PAF of 45.3% (nearly half of dementias theoretically preventable); the new factors are uncorrected vision impairment and high LDL-C, added to less education, hearing impairment, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, TBI, air pollution, and social isolation.
- New meta-analyses: hearing loss was associated with HR 1.37 (1.00–1.87, I²=80%, n=666,370) for dementia; depression was associated with RR 2.25 (1.69–2.98, I²=82.8%) at 10–14 years. Hearing aid use was associated with 17% lower dementia risk (0.77–0.90) and 19% lower cognitive decline (0.76–0.87) in 8 cohorts with 126,903 participants.
- Vision impairment was associated with pooled RR 1.47 (1.36–1.60) for dementia in 14 cohorts (6,204,827 older adults); each 1 mmol/L higher LDL-C was associated with 8% increased all-cause dementia incidence (1.08, 1.03–1.14).
- Anti-amyloid antibodies: lecanemab reduced worsening by 0.45 CDR-SB points versus placebo at 18 months; donanemab showed iADRS -10.19 versus -13.11. Effects were small, with ARIA, monitoring, and cost concerns. Cholinesterase inhibitors showed modest long-term benefit and lower mortality in observational studies.
Methods
- International, interdisciplinary commission used a triangulation framework, prioritising systematic reviews/meta-analyses and performing new meta-analyses where needed; commissioners wrote sections, debated, and unanimously agreed on the evidence.
- New random-effects meta-analyses were performed for hearing loss and depression; PAF calculation incorporated 14 risk factors using the largest recent worldwide meta-analyses for prevalence and relative risks, with the HUNT study (37,000 participants aged ≥45) used to estimate communality/clustering and weighted PAF adjusted for communality.
- Hearing loss search was updated to March 20, 2023, across PubMed, Ovid Embase, PsycINFO, Web of Science, Cochrane Library, PROSPERO, and Centre for Reviews and Dissemination.
Limitations
- Stated: most global research is from HICs, with LMICs under-represented; HUNT had lower alcohol abuse prevalence and lacked ethnic diversity; no worldwide LDL-C prevalence estimate existed, so a single cohort estimate was used; new meta-analyses were not pre-registered; air pollution could not be meta-analysed; selection criteria were subjective; risk modification affects populations but does not guarantee any individual avoids dementia.
- Stated: many associations may be only partly causal; observational evidence and reverse causation are concerns, especially for late-life risk factors and prodromal dementia.
- Evident from the text: anti-amyloid trials excluded many multimorbid and diverse patients (e.g., only 8% [19/237] of a community-based Mayo Clinic sample with amyloid positivity and MCI/mild dementia would have met lecanemab eligibility), and biomarker studies are largely in White populations, limiting generalisability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
238 Valid · 54 Not valid · 106 Not checked · 157 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study of six community cohorts, comprising 4,354 people aged >80 years who had died in the US or UK, analysed six types of neuropathology and found 91% of people died with two or more types of neuropathology.(20)”
§ These authors had an equal contribution. > Cognitive vulnerability, brain maintenance and cognitive reserve
What the sources say
- Disputedcites [20] 20. Nichols E, Merrick R, Hay SI, Himali D, Himali JJ, Hunter S, et al. The prevalence, correlation, and cooccurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. Lancet Healthy Longev. 2023;4(3):e115-e25. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainn = 4,354- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A UK study of 15,924 participants found that women born more recently were catching up with me n's higher memory and fluency scores, as women's access to education increases.(59)”
§ These authors had an equal contribution. > Female sex and gender
What the sources say
- Disputedcites [59] 59. Bloomberg M, Dugravot A, Dumurgier J, Kivimaki M, Fayosse A, Steptoe A, et al. Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies. Lancet Public Health. 2021;6(2):e106-e15. sourceExperimental — accuracy not yet measured
The Findings report 15,924 participants and a shift from higher fluency scores in men in earlier birth cohorts to higher scores in women in later cohorts. But women had higher memory scores than men in every birth cohort, contrary to the claim that they were catching up with men's higher memory scores. The Discussion also links the cohort patterns to changes in access to education. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a causen = 15,924- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Some studies are noteworthy because of longer follow-up but no studies reported those who developed dementia soon after sleep duration ascertainment separately from those who developed it after longer periods. (280, 296-301)”
§ These authors had an equal contribution. > Sleep
What the sources say
- Not matchedcites [280] 280. Selbaek-Tungevag S, Selbaek G, Strand BH, Myrstad C, Livingston G, Lydersen S, et al. Insomnia and risk of dementia in a large population-based study with 11-year follow-up: The HUNT study. J Sleep Res. 2023:e13820.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [296] 296. Virta JJ, Heikkila K, Perola M, Koskenvuo M, Raiha I, Rinne JO, Kaprio J. Midlife sleep characteristics associated with late life cognitive function. Sleep. 2013;36(10):1533-41, 41A. source
- Partly supportedcites [297] 297. Luojus MK, Lehto SM, Tolmunen T, Brem AK, Lonnroos E, Kauhanen J. Self-reported sleep disturbance and incidence of dementia in ageing men. J Epidemiol Community Health. 2017;71(4):329-35. sourceExperimental — accuracy not yet measured
The Study population section (page unavailable) reports a mean follow-up of 21.9 years and says men diagnosed with dementia within two years of baseline were excluded. This study therefore did not report early and later diagnoses separately, but it cannot establish the broader claim that no studies did so. (LLM, conf=0.78)
- Partly supportedcites [298] 298. Lutsey PL, Misialek JR, Mosley TH, Gottesman RF, Punjabi NM, Shahar E, et al. Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study. Alzheimers Dement. 2018;14(2):157-66. sourceExperimental — accuracy not yet measured
The Discussion describes approximately 15 years between sleep assessment and the neurocognitive exam, and Results §3.3 reports incident-dementia estimates without separating early from later cases. This supports the statement for this study, but the paper does not establish that no studies made that distinction. (LLM, conf=0.78)
- Partly supportedcites [299] 299. Bokenberger K, Strom P, Dahl Aslan AK, Johansson AL, Gatz M, Pedersen NL, Akerstedt T. Association Between Sleep Characteristics and Incident Dementia Accounting for Baseline Cognitive Status: A Prospective Population-Based Study. J Gerontol A Biol Sci Med Sci. 2017;72(1):134-9. sourceExperimental — accuracy not yet measured
The Discussion reports a 17-year follow-up, supporting the longer-follow-up part of the sentence. It also says the study excluded people who developed dementia within three years of baseline, with other cutoffs tested in sensitivity analyses. It does not establish the broader claim that no studies reported early and later dementia cases separately. (LLM, conf=0.82)
- Disputedcites [300] 300. Larsson SC, Wolk A. The Role of Lifestyle Factors and Sleep Duration for Late-Onset Dementia: A Cohort Study. J Alzheimers Dis. 2018;66(2):579-86. sourceExperimental — accuracy not yet measured
The Methods (Statistical analysis; page unavailable) say this study repeated its sleep-duration analysis after excluding dementia cases diagnosed in the first five or ten years. The Results (page unavailable) report separate estimates for the full follow-up and after each exclusion, directly distinguishing later diagnoses from the analysis that included early diagnoses. The paper does not, however, report a standalone estimate for early diagnoses. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
- Not matchedcites [301] 301. Sabia S, Dugravot A, Leger D, Ben Hassen C, Kivimaki M, Singh-Manoux A. Association of sleep duration at age 50, 60, and 70 years with risk of multimorbidity in the UK: 25-year follow-up of the Whitehall II cohort study. Plos Med. 2022;19(10):e1004109.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In a London study quantifying this, 209/1510 (13.6%) participants in a prospective cohort with median age 77 years, were admitted to hospital at least once over a follow-up of 30 months or more. (550)”
§ These authors had an equal contribution. > Hospital admissions and delirium
What the sources say
- Disputedcites [550] 550. Richardson SJ, Davis DHJ, Stephan BCM, Robinson L, Brayne C, Barnes LE, et al. Recurrent delirium over 2. 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study. Age Ageing. 2021;50(3):914-20. sourceExperimental — accuracy not yet measured
The Methods (Population; page unavailable) identify the cohort as CFAS II-Newcastle, not a London cohort. The Results (Characteristics; page unavailable) report 363 of 1,328 participants admitted during a one-year recruitment period, rather than 209 of 1,510 over at least 30 months; Table 1 gives a mean age of 82, not a median age of 77. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The overall numbers of people with dementia have increased more recently in lower income countries due to greater percentage increase in longevity. (5, 6)”
§ These authors had an equal contribution. > Introduction
What the sources say
- Partly supportedcites [5] 5. Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255-65. sourceExperimental — accuracy not yet measured
The Introduction and Burden of neurological disorders sections link rising numbers of people affected by neurological disorders, particularly in low- and middle-income countries, to population growth and ageing. They do not establish that dementia cases specifically rose more recently in lower-income countries or that a greater percentage increase in longevity there caused the rise. Page numbers were not available in our copy. (LLM, conf=0.85)
- Partly supportedcites [6] 6. Maestre G, Carrillo M, Kalaria R, Acosta D, Adams L, Adoukonou T, et al. The Nairobi DeclarationReducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs. Alzheimers Dement. 2023. sourceExperimental — accuracy not yet measured
The Nairobi Declaration (page unavailable) says that by 2030 most people with dementia will live in low- and middle-income countries and describes a high burden there. It does not say that dementia numbers have recently increased in those countries or attribute such an increase to a greater percentage rise in longevity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
302 more claims · 147 with their cited sources checked
Create a free account to see all 555 claims and every source verdict.
- It may state two separate claims as one. 229
- Probably not a substantial claim. 48
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, knowledge of the modifiability of one’s own dementia risk can contribute to healthier lifestyle decisions”
From Sociodemographic differences in dementia prevention knowledge in Germany: Implications for targeted health communication (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The low recognition of hearing impairment and poor sleep as risk factors for dementia may be attributed to their relatively recent identification as candidate modifiable risk factors. 1 , 2”
From Awareness and knowledge of dementia risk reduction among current and future health professionals: A survey study (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lifestyle interventions, including exercise, cognitive training, and vascular risk management, remain essential in delaying symptom onset.13”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypercholesterolemia, defined by elevated plasma low‐density lipoprotein (LDL) cholesterol, is a well‐established risk factor not only for cardiovascular disease (Borén et al. 2022; Steinberg 2013; Tabas et al. 2015; Boffa and Koschinsky 2019), but also for cognitive decline and dementia in later life (Kivipelto et al. 2001; Kivipelto and Solomon 2006; Livingston et al. 2024; Sparks et al. 2000, 2”
From LDL Cholesterol Modulates Astrocyte Metabolism, Lipid Handling, and Morphology: Evidence From In Vitro and In Vivo Models (2026) · cites this paper as Livingston et al. 2024
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Multidomain interventions that incorporate physical exercise have emerged as promising non-pharmacological strategies for dementia prevention [417,418].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [417]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“209/1510 (13.6%) participants in a prospective cohort with median age 77 years, were admitted to hospital at least once”
§ These authors had an equal contribution. > Hospital admissions and delirium
Reported 13.6 · recomputed 13.84106
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“hallucinations 0.09, -0.14--0.04; I 2 =0”
§ These authors had an equal contribution. > Management
Reported 0.09 · recomputed -0.09
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Livingston, 2020, Dementia prevention, intervention, and care: 2020 report of the Lancet Commission, Lancet, 396, 413, 10.1016/S0140-6736(20)30367-6”
Cited work 10.1016/s0140-6736(20)30367-6 · retracted 2023-05-01 · notice 10.1016/s2468-2667(23)00083-x · this paper published 2024-08
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Self-citationThe Mini‐Mental State Examination: A Comprehensive Review
Tombaugh, T. N., & McIntyre, N. J. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01992.x · Cited by 5,152
Guthold, R., Stevens, G. A., Riley, L. M., & Bull, F. C. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30357-7 · Cited by 4,819
A new data set of educational attainment in the world, 1950–2010
Barro, R. J., & Lee, J. W. (2013) · Journal of Development Economics · doi:10.1016/j.jdeveco.2012.10.001 · Cited by 4,333
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Cited by
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Donanemab: Appropriate use recommendations
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278
“We also recommend discontinuing treatment in patients who develop a third ARIA event (even if mild and asymptomatic), those with a seriously symptomatic episode of ARIA and in patients who develop a new medical indication for treatment with an anticoagulant.”
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Baker, L. D., Espeland, M. A., Whitmer, R. A., Snyder, H. M., Leng, X., Lovato, L., Papp, K. V., Yu, M., Kivipelto, M., Alexander, A. S., et al. (2025) · JAMA · doi:10.1001/jama.2025.12923 · Cited by 270
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“377 Therefore, the antiageing interventions discussed herein primarily address the systemic effects of ageing.”
Metadata
- Authors
- Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., Samus, Q., Shirai, K., Singh-Manoux, A., Schneider, L. S., Walsh, S., Yao, Y., Sommerlad, A., & Mukadam, N.
- Affiliations
- University College London (GB)
- University of Exeter (GB)
- Oslo University Hospital (NO)
- National Institute of Mental Health and Neurosciences (IN)
- The University of Melbourne (AU)
- University of Nottingham (GB)
- University of Manchester (GB)
- University of Cambridge (GB)
- Hospital Alemão Oswaldo Cruz (BR)
- Drexel University (US)
- University of California Davis Medical Center (US)
- University of Washington (US)
- Makerere University (UG)
- Dalhousie University (CA)
- Johns Hopkins University (US)
- The University of Osaka (JP)
- University of Southern California (US)
- Peking University (CN)
- Corresponding author
- Livingston, Gill
- ORCID
- Livingston, Gill
- Huntley, Jonathan
- Liu, Kathy Y
- Costafreda, Sergi G
- Selbæk, Geir
- Alladi, Suvarna
- Banerjee, Sube
- Burns, Alistair
- Brayne, Carol
- Fox, Nick C
- Ferri, Cleusa P
- Gitlin, Laura N
- Howard, Robert
- Kales, Helen C
- Larson, Eric B
- Nakasujja, Noeline
- Rockwood, Kenneth
- Samus, Quincy
- Shirai, Kokoro
- Schneider, Lon S
- Walsh, Sebastian
- Yao, Yao
- Sommerlad, Andrew
- Mukadam, Naaheed
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 404
- Issue
- 10452
- Pages
- 572-628
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4401164724
- Cited by
- 3,860
- References
- 637
- Citations by year
- 2026: 1901 · 2025: 1762 · 2024: 197
- FWCI
- 1128.86
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion)
- Apollo (cc-by)
- Funders
- Alzheimer's Society
- National Institute for Health and Care Research
- University College London
- University College London Hospitals NHS Foundation Trust
- Medical Research Council (MR/S021418/1, MR/S011676/1, MR/Y014154/1, MR/R024227/1)
- Economic and Social Research Council
- Japan Society for the Promotion of Science (21KK0168, 23K24610)
- National Institute on Aging (R01AG056477)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Health Professions › Speech and Hearing › Hearing Loss and Rehabilitation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- dementia prevention, dementia interventions, dementia care, Alzheimer's disease, mild cognitive impairment, cognitive decline, hearing loss, age-related hearing loss, hearing aids, dementia risk, hazard ratio
- MeSH terms
- Dementia, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01296-0
- The paper
- Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., . . . Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. https://doi.org/10.1016/s0140-6736(24)01296-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.